Overview

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

To define the relative efficacy, safety and tolerability profiles of oral daily MBX-2982 at three different daily doses vs. placebo and sitagliptin 100 mg when administered for up to 4 weeks in patients that are treatment-naive or taking a single anti-diabetic medication (non-TZD, non-injectable).

Phase:

Phase 2

Details

Lead Sponsor:

CymaBay Therapeutics, Inc.

Treatments:

Sitagliptin Phosphate